Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511069 | 1.00 | IRAK4 (0.33) | IRAK4 | |
| SCHEMBL4378117 | 0.90 | IRAK4 (0.37) | IRAK4 | |
| SCHEMBL4378128 | 0.90 | IRAK4 (0.37) | IRAK4 | |
| SCHEMBL9865626 | 0.81 | LMNA (0.39) | IRAK4 | |
| SCHEMBL5215585 | 0.81 | LMNA (0.39) | IRAK4 | |
| SCHEMBL5505248 | 0.77 | — | — | |
| SCHEMBL22354600 | 0.75 | IRAK4 (0.42) | IRAK4 | |
| SCHEMBL5994524 | 0.75 | IRAK4 (0.42) | IRAK4 | |
| SCHEMBL14285588 | 0.70 | IRAK4 (0.41) | IRAK4 | |
| SCHEMBL5991543 | 0.70 | IRAK4 (0.41) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547685-B2 | Therapeutic substituted pyrrolidone compounds | ALLERGAN, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080015239-A1 | Therapeutic Substituted Pyrrolidone Compounds | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015239-A1 | Therapeutic Substituted Pyrrolidone Compounds | TPMT, TYMP, PIGO | IRAK4 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.